Defining Predictors of Weight Loss Response to Lorcaserin

Context Individual responses to weight loss (WL) medications vary widely and prediction of response remains elusive. Objective We investigated biomarkers associated with use of lorcaserin (LOR), a 5HT(2c)R agonist that targets proopiomelanocortin (POMC) neurons that regulate energy and glucose homeostasis, to identify predictors of clinical efficacy. Methods Thirty individuals with obesity were treated with 7 days of placebo and LOR in a randomized crossover study. Nineteen participants continued on LOR for 6 months. Cerebrospinal fluid (CSF) POMC peptide measurements were used to identify potential biomarkers that predict WL. Insulin, leptin, and food intake during a meal were also studied. Results LOR induced a significant decrease in CSF levels of the POMC prohormone and an increase in its processed peptide beta-endorphin after 7 days; beta-endorphin/POMC increased by 30% (P < .001). This was accompanied by a substantial decrease in insulin, glucose, and homeostasis model assessment of insulin resistance before WL. Changes in CSF POMC peptides persisted after WL (6.9%) at 6 months that were distinct from prior reports after diet alone. Changes in POMC, food intake, or other hormones did not predict WL. However, baseline CSF POMC correlated negatively with WL (P = .07) and a cutoff level of CSF POMC was identified that predicted more than 10% WL. Conclusion Our results provide evidence that LOR affects the brain melanocortin system in humans and that effectiveness is increased in individuals with lower melanocortin activity. Furthermore, early changes in CSF POMC parallel WL-independent improvements in glycemic indexes. Thus, assessment of melanocortin activity could provide a way to personalize pharmacotherapy of obesity with 5HT(2c)R agonists.

Automated summary

The study found that Lorcaserin (LOR) affects the brain melanocortin system in humans and is more effective in individuals with lower melanocortin activity.